| Sumario: | Background: CEMETERY is a micronized, injectable form of ALLODERM (LifeCell Corporation, Branchberg, New Jersey), an allogeneic dermal matrix product developed as a filler substance for cosmetic use. Recently, CYMETRA has been reported to be effective in the healing of recalcitrant sinus tracts in two patients. Objective: The objective of the authors' study was to evaluate the safety and efficacy of CYMETRA as an adjuvant in the treatment of a variety of chronic wounds. Methods: A retrospective chart review was performed for patients who were treated with CYMETRA at the CURE Wound Care Center at the University of Miami, Miami, Florida. Results: Patients with various types of chronic ulcers, including pyoderma gangrenosum, eosinophilic fasciitis, chronic pressure ulcers, post-operative ulcers, venous insufficiency ulcers, and livedo vasculitis, were treated with CYMETRA injections. All patients had refractory disease and failed to respond to prior treatments, which included APLIGRAF (Organogenesis, Canton, Massachusetts), Dermagraft (Smith & Nephew, Largo, Florida), V.A.C. THERAPY (KCI Inc., San Antonio, Texas), compression, etanercept, mycophenolate mofetil, prednisone, infliximab, cyclosporine, antibiotics, debridement, intralesional triamcinolone acetonide, and granulocyte/macrophage colony-stimulating factor (GMCSF). Of the 13 patients treated with CYMETRA, nine patients' ulcers (69%) healed completely. Conclusions: CYMETRA was well tolerated, and the majority of patients achieved complete healing of their ulcers after treatment.
|
|---|